Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures

Journal of Neurochemistry

Volumn 82, Issue 6, 2002, Pages 1465-1471

  Carpenedo, Raffaella ^a   Meli, Elena ^a   Peruginelli, Fiamma ^a   Pellegrini Giampietro, Domenico E ^a   Moroni, Flavio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

(m nitrobenzoyl) alanine; Kynurenic acid; Neuroprotection; Oxygen glucose deprivation; Quinolinic acid; Ro 61 8048

Indexed keywords

(3 NITROBENZOYL) ALANINE; 3 HYDROXYKYNURENINE; 3,4 DIMETHOXY [ N 4 (NITROPHENYL)THIAZOL 2 YL]BENZENESULFONAMIDE; GLUCOSE; KYNURENINE 3 MONOOXYGENASE; KYNURENINE 3 MONOOXYGENASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; NITROBENZENE DERIVATIVE; OXYGEN; QUINOLINIC ACID; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CELL DEATH; CONTROLLED STUDY; CULTURE MEDIUM; GLUCOSE METABOLISM; HIPPOCAMPUS; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; TISSUE CULTURE;

ALANINE; ANIMALS; BRAIN ISCHEMIA; CELL DEATH; CELL HYPOXIA; CULTURE MEDIA, CONDITIONED; ENZYME INHIBITORS; GLUCOSE; HIPPOCAMPUS; KYNURENIC ACID; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; MIXED FUNCTION OXYGENASES; NEURONS; NEUROPROTECTIVE AGENTS; PYRAMIDAL CELLS; QUINOLINIC ACID; RATS; SULFONAMIDES; THIAZOLES;

ANIMALIA; HIPPOCAMPUS HIPPOCAMPUS;

EID: 0036734822     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2002.01090.x     Document Type: Article

References (35)

1. Abdel-Hamid K. M. and Tymianski M. (1997) Mechanisms and effects of intracellular calcium buffering on neuronal survival in organotypic hippocampal cultures exposed to anoxia/aglycemia or to excitotoxins. J. Neurosci. 17, 3538-3553.
2. Bonfoco E., Krainc D., Ankarcrona M., Nicotera P. and Lipton S. A. (1995) Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc. Natl. Acad. Sci. USA 92, 7162-7166.
3. Carpenedo R., Chiarugi A., Russi P., Lombardi G., Carlà V., Pellicciari R., Mattoli L. and Moroni F. (1994) Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenic acid and have sedative and anticonvulsant activities. Neuroscience 61, 237-244.
4. Carpenedo R., Pittaluga A., Cozzi A., Attucci S., Galli A., Raiteri M. and Moroni F. (2001) Presynaptic kynurenate sensitive receptors inhibit glutamate release. Eur J. Neurosci. 13, 2141-2147.
5. Chiarugi A., Carpenedo R., Molina M. T., Mattoli L., Pellicciari R. and Moroni F. (1995) Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J. Neurochem. 65, 1176-1183.
6. Chiarugi A., Cozzi A., Ballerini A., Massacesi L. and Moroni F. (2000a) Kynurenine 3-monooxygenase activity and neurotoxic kynurenine metabolites increase in the central nervous system of rats with experimental allergic encephalomyelitis. Neuroscience 102, 687-695.
7. Chiarugi A., Dello Sbarba P., Paccagnin A., Donnini S., Filippi S. and Moroni F. (2000b) Combined inhibition of indoleamine 2,3-dioxygenase and nitric oxide synthase modulates neurotoxin release by interferon-γ-activated macrophages. J. Leukoc. Biol. 68, 260-266.
8. Chiarugi A., Calvani M., Meli E., Traggiai E. and Moroni F. (2001a) Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J. Neuroimmunol. 120, 190-198.
9. Chiarugi A., Meli E. and Moroni F. (2001b) Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 77, 1310-1318.
10. Connick J., Heywood G. C., Sills G. J., Thomson G. G., Brodie M. J. and Stone T. W. (1992) Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen. Pharmacol. 23, 235-239.
11. Cozzi A., Carpenedo R. and Moroni F. (1999) Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl) thiazol-2yl]-benzensulfonamide (Ro 61 8048) in models of focal or global brain ischemia. J. Cereb. Blood Flow Metab. 19, 771-777.
12. Gramsbergen J. B. P., Hodgkins P. S., Rassoulpour A., Turski W. A., Guidetti P. and Schwarcz R. (1997) Brain-specific modulation of kynurenic acid synthesis in the rat. J. Neurochem. 69, 290-298.
13. Hilmas C., Pereira E. F. R., Alkondon M., Rassoulpour A., Schwarcz R. and Albuquerque E. X. (2001) The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non α7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21, 7463-7473.
14. Hodgkins P. S. and Schwarcz R. (1998) Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate. Eur J. Neurosci. 10, 1986-1984.
15. Moroni F. (1999) Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J. Pharmacol. 375, 87-100.
16. Moroni F., Russi P., Lombardi G., Beni M. and Carlà V. (1988) Presence of kynurenic acid in the mammalian brain. J. Neurochem. 51, 177-181.
17. Moroni F., Russi P., Gallo-Mezo M. A., Moneti G. and Pellicciari R. (1991) Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine. J. Neurochem. 57, 1630-1635.
18. Moroni F., Meli E., Peruginelli F., Chiarugi A., Cozzi A., Picca R., Romagnoli P., Pellicciari R. and Pellegrini-Giampietro D. E. (2001) Poly (ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ 8, 921-932.
19. Newell D. W., Barth A., Ricciardi T. N. and Malouf A. T (1997) Glycine causes increased excitability and neurotoxicity by activation of NMDA receptors in the hippocampus. Exp Neurol. 145, 235-244.
20. Okuda S., Nishiyama N., Saito H. and Katsuki H. (1998) 3-Hydroxy-kynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 70, 299-307.
21. Pellegrini-Giampietro D. E., Cozzi A., Peruginelli F., Leonardi P., Meli E., Pellicciari R. and Moroni F. (1999a) 1-Aminoindane-1,5-dicarboxylic acid and (s)-(+)-2-(3′-carboxybiciclo[1.1.1]pentyl)-glycine, two mGlu 1 receptor-preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischemia. Eur. J. Neurosci. 11, 3637-3647.
22. Pellegrini-Giampietro D. E., Peruginelli F., Meli E., Cozzi A., Albani Torregrossa S., Pellicciari R. and Moroni F. (1999b) Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time course and mechanisms. Neuropharmacology 38, 1607-1621.
23. Pringle A. K., Iannotti F., Wilde G. J. C., Chad J. E., Seeley P. J. and Sundstrom L. E. (1997) Neuroprotection by both NMDA and non-NMDA receptor antagonists in in vitro ischemia. Brain Res. 755, 36-46.
24. Roever S., Cesura A. M., Huguenin P., Kettler R. and Szente A. (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-yl) benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem 40, 4378-4385.
25. Russi P., Alesiani M., Lombardi G., Davolio P., Pellicciari R. and Moroni F. (1992) Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem. 59, 2076-2080.
26. Schwarcz R., Whetsell W. O. and Mangano R. M. (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219, 316-318.
27. Stone T. W. (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45, 309-379.
28. Stone T. W. (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol. Sci. 21, 149-154.
29. Stone T. W. and Connick J. (1985) Quinolinic acid and other kynurenines in the central nervous system. Neuroscience 15, 507-617.
30. Turecek R. and Trussel L. O. (2001) Presynaptic glycine receptors enhance transmitter release at a mammalian central synapse. Nature 411, 587-590.
31. Turski W. A., Nakamura M., Todd W. P., Carpenter B. K., Whetsell W. O. and Schwarcz R. (1988) Identification and quantification of kynurenic acid in human brain tissue. Brain Res. 454, 164-169.
32. Urenjak J. and Obrenovitch T. P. (2000) Neuroprotective potency of kynurenic acid against excitotoxicity. Neuroreport 11, 1-4.
33. Vasquez S., Garner B., Sheil M. M. and Truscott R. J. (2000) Characterization of the major autoxidation products of 3-hydroxykynurenine under physiological conditions. Free Radic. Res. 32, 11-23.
34. Wei H., Leeds P., Chen R. W., Wei W., Leng Y., Bredesen D. E. and Chuang D. M. (2000) Neuronal apoptosis induced by pharmacological concentrations of 3-hydroxykynurenine: characterization and protection by dantrolene and Bcl-2 overexpression. J. Neurochem. 75, 81-90.
35. Wu H. Q., Guidetti P., Goodman J. H., Varasi M., Ceresoli-Borroni G., Speciale C., Scharfman H. E. and Schwarcz R. (2000) Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo. Neuroscience 97, 243-251.